MYCN and prostate cancer: Considering that transition from CRPC to neuroendocrine prostate cancer (NEPC) is driven by N-Myc, which also abrogates AR transcriptional program, and that N-Myc is functionally complementary to c-Myc in various processes54,55, it is now evident that Myc family members are key to prostate cancer etiology and resistance to standard-of-care therapies.